



Acrux Limited (ACR:ASX)

ASX Announcement



9 October 2026

Investor webinar: Female Testosterone MDTs and recent FDA feedback

Melbourne, Australia; 9 October 2026: Acrux invites shareholders and investors to attend a live investor webinar on **Monday 12 October 2026 at 3.00pm AEDT**.

Acrux CEO John Warmbrunn will provide an update on Female Testosterone MDTs, including recent feedback from the U.S. Food and Drug Administration (FDA) and the Company's Phase III development pathway.

The webinar will also cover key themes from the FDA's recent public workshop on testosterone use in menopausal women, followed by a live investor Q&A with management.

Date: Monday 12 October 2026

Time: 3.00pm AEDT

Register: Participants can register for the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_zr980BfsSLK34AF53x3xHw#/registration

Once registered, participants will receive a confirmation email containing details on how to access the webinar.

Authorised for release by the CEO and Managing Director of Acrux Limited.

END.

For more information, please contact:

John Warmbrunn

CEO & Managing Director

E: john.warmbrunn@acrux.com.au

P: + 61 3 8379 0100

Joanna Johnson

CFO & Company Secretary

E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

Media Relations

Julia Maguire

The Capital Network

E: julia@thecapitalnetwork.com.au

P: + 61 2 7257 7338

About Acrux:

Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Click here to sign up to our InvestorHub and keep up to date with company news and latest developments or for further information on Acrux Limited visit www.acrux.com.au

